Clinical trial registry record

TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission

A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 4, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07563920
Last registry update
May 4, 2026
Status
Not Yet Recruiting
Phase
Phase not reported
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment
93
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
93
Population
ALL · 55 Years to 75 Years
Duration
2026-06-01 to 2030-06-01
Intervention
Thiotepa; Busulfan (BU); Fludarabine; Haploidentical Peripheral Blood Stem Cell Transplantation
Comparator
Not reported
Outcomes measured
1-year Relapse-Free Survival (RFS) — 12 months after transplantation; Overall Survival (OS) — 12 months after transplantation; Incidence of Acute Graft-Versus-Host Disease (aGVHD) — Up to 180 days after transplantation; Incidence of Chronic Graft-Versus-Host Disease (cGVHD) — 12 months after transplantation; Non-Relapse Mortality (NRM) — 12 months after transplantation
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Stem cells · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

stem cells
Read the original source →Export JSON